Refresh your memory of 4 CGM systems that received FDA-approval in 2018. Each one offers innovative features to help enhance diabetes care.
Dexcom G6® was FDA-approved in March 2018 for patients aged ≥2 years. The one-touch applicator easily inserts a small sensor subcutaneously that lasts for 10 days. The sensor continuously measures glucose levels every 5 minutes and transmits the data to a touch screen receiver or a compatible smart phone. Patients receive a 20-minute alert for hyperglycemia and hypoglycemia and they can customize alerts for 2 periods of time within 24 hours. The Dexcom G6® also has integration with Siri, Google Fit, Apple Watch, and CLARITY® (web-based software that gives patients access to glucose patterns, trends, and statistics in interactive reports they can share with their provider).
Eversense® Implantable CGM was approved in June 2018 for adults aged ≥18 years; the FDA expanded certification to nurse practitioners and physicians assistants in November 2018. It was the first approved CGM to include an implantable glucose-detecting sensor with a 90-day lifespan, which is inserted subcutaneously on the upper arm by a healthcare provider. Novel light-sensing technology measures glucose levels and then sends the data to the removable transmitter worn on the skin over the sensor. The transmitter then sends the data to the Eversense mobile app which vibrates when glucose levels are too high or too low and displays data in easy-to-read charts that can be shared with up to 10 people.
Abbott FreeStyle® Libre 14 Day system was approved in July 2018 for patients aged ≥18 years with no fingerstick calibration required. The CGM system is comprised of a handheld reader and a 14-day sensor about the size of 2 stacked US quarters that is self-applied behind the upper arm. The handheld reader or smartphone scans the sensor in 1 second, stores up to 90 days of glucose data, and shows a graph of the last 8 hours of glucose history. The sensor does not interfere with acetaminophen, is water resistant, and transmits through clothing. The FreeStyle® Libre 14 day system is used by >1 500 000 people in 46 countries.
MiniMed® 630G and 670G are hybrid closed loop systems that insert the Guardian™ Sensor 3 just below the skin to measure glucose levels in the interstitial fluid; SmartGuard™ technology alerts patients when insulin dips below preset level and automatically pauses insulin delivery for 2 hours, giving patients time to recover. The 630G was originally approved in June 2017 for patients aged ≥16 years and the 670G was originally approved in September 2016 for patients aged ≥14 years; in February 2018, however, the FDA expanded indication for both systems, so sensors could be inserted in the upper arm and abdomen.
In 2018, the FDA issued approvals for several continuous glucose monitors (CGMs), and an expanded indication for a closed-loop artificial pancreas system. Since then, these systems have been rolled out and are currently being marketed in the US. This short slideshow offers compact summaries on 4 of these products which all offer innovative features like extended sensor wear-time, elimination of daily finger stick calibration, and integration with Siri and Google Fit apps.